What is CaroGen?
CaroGen Corporation is dedicated to pioneering immunotherapy and vaccine solutions through its proprietary AVIDIO platform, which leverages RNA technology. The company is focused on developing transformative treatments for challenging diseases, including cancer and chronic hepatitis B. Its pipeline features two key candidates, CARG-201 for hepatitis B and CARG-2020 for ovarian cancer, both currently in advanced pre-clinical development. Significant backing from entities such as the NIH and DoD has supported CaroGen's research and development efforts, reinforcing its commitment to addressing unmet medical needs in immuno-oncology and infectious diseases.
How much funding has CaroGen raised?
CaroGen has raised a total of $2.2M across 2 funding rounds:
Angel/Seed
$150K
Private Equity
$2.1M
Angel/Seed (2013): $150K with participation from Connecticut Innovations
Private Equity (2016): $2.1M, investors not publicly disclosed
Key Investors in CaroGen
Connecticut Innovations
Connecticut Innovations (ctinnovations.com) is Connecticuts strategic venture capital arm and quasipublic investment agency, providing equity and debt financing, strategic guidance, and connections to help innovative, growing companies in the state scale, with dedicated funds for sectors like AI/quantum, climate tech, and biosciences.
What's next for CaroGen?
With the recent infusion of major strategic investment, CaroGen is poised to accelerate the development and potential commercialization of its promising therapeutic candidates. The company's focus on late-stage pre-clinical studies for CARG-201 and CARG-2020 indicates a near-term transition towards clinical trials. This substantial backing, coupled with a robust patent portfolio, positions CaroGen to further its mission of delivering groundbreaking treatments to patients globally. Future endeavors will likely involve expanding its research capabilities and potentially forging strategic partnerships to enhance market reach and therapeutic impact.
See full CaroGen company page
